Dupilumab

度普利尤单抗

Report date: 2026/05/12 20:00:17
First In Class

Base Information

Drug NameDupilumab
Drug Alias Name度匹鲁单抗Dupilumabum度匹芦人单抗Dupixent达必妥 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-13 inhibitorsInterleukin-4 inhibitorsInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-13Interleukin-4Interleukin-4 receptor subunit alpha
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Allergic Fungal RhinosinusitisPrurigo Nodularis +[44] 
Global Approved IndicationsDermatitis, Atopic
Approved Indications in ChinaDermatitis, Atopic
Original Approved Country/TerritoryUnited States
Original Approved Date2017/03/28
Country/TerritoryCzechiaBelgiumBulgaria +[50] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofiRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofi-Aventis GroupeUniversity Medical Center GroningenThe Brigham and Women's Hospital +[21] 
Inactive CompaniesUT Health San AntonioUniversity Of South FloridaJohns Hopkins University +[7] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Allergic Fungal RhinosinusitisPrurigo Nodularis +[36] 
Inactive IndicationsMilk HypersensitivityHypersensitivity, ImmediateHypersensitivity +[8] 

Other Information

ATC CodeD11AH05
Related LinksWikipediaDrugBankKEGG